Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Roswell Park Cancer Institute
Thomas Jefferson University
Institut Claudius Regaud
The Methodist Hospital Research Institute
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
University of Utah
H. Lee Moffitt Cancer Center and Research Institute
University of Rochester
Bio-Thera Solutions
Centre Hospitalier Universitaire de Nice
Centre Hospitalier Universitaire de Nice
Institut Cancerologie de l'Ouest
Institut Claudius Regaud
UNC Lineberger Comprehensive Cancer Center
Amgen
Merck Sharp & Dohme LLC
Iovance Biotherapeutics, Inc.
Almirall, S.A.
CivaTech Oncology
Immorna Biotherapeutics, Inc.
Mayo Clinic
Klein Buendel, Inc.
Dragonfly Therapeutics
Dragonfly Therapeutics
Immunocore Ltd
Seagen Inc.
Merck Sharp & Dohme LLC
Centre Oscar Lambret
BioNTech SE
Dana-Farber Cancer Institute
Emory University
McGuire Institute
Endeavor Biomedicines, Inc.
Case Comprehensive Cancer Center
Hasumi International Research Foundation
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Institute of Oncology Ljubljana
Pfizer
Melanoma Institute Australia
H. Lee Moffitt Cancer Center and Research Institute
San Gallicano Dermatological Institute IRCCS
Bristol-Myers Squibb
Institute of Oncology Ljubljana
Institute of Oncology Ljubljana
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Case Comprehensive Cancer Center
University Hospital, Caen